Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study
Table 2
Eicosanoids values at baseline and following aspirin challenge in AIA and ATA patients. Results of eicosanoids were recalculated as parts per million (ppm) of palmitic acid (PA).
AIA ()
ATA ()
(ANOVA)
Baseline
Challenge
Baseline
Challenge
After the challenge
PGD2
0.54
(parts/million of PA)
3.18
3.69
4.27
3.85
GC/MS
PGD2
Unable
(parts/million of PA)
3.56
3.00
2.99
3.33
HPLC/MS/MS
9α11βPGF2
Unable
(parts/million of PA)
1.24
1.30
0.61
0.75
GC/MS
PGF2α
0.82
(parts/million of PA)
0.97
0.86
0.64
0.49
GC/MS
6-keto-PGF1α
0.74
(parts/million of PA)
32.15
32.96
16.80
16.12
GC/MS
6-keto-PGF1α
0.11
(parts/million of PA)
32.08
32.51
15.60
18.15
HPLC/MS/MS
11-dehydro TXB2
0.82
(parts/million of PA)
21.67
21.40
15.10
15.55
GC/MS
11-dehydro TXB2
0.66
(parts/million of PA)
19.69
21.48
14.49
14.65
HPLC/MS/MS
LTC4
*
*
0.003*
(parts/million of PA)
9.22
6.61
5.40
3.24
HPLC/MS/MS
LTD4
0.67
(parts/million of PA)
2.18
2.25
2.68
2.16
HPLC/MS/MS
LTE4
*
*
0.03*
(parts/million of PA)
5.19
6.38
4.88
6.54
HPLC/MS/MS
Total cysLTs
0.33
(parts/million of PA)
19.74
15.70
14.14
12.94
HPLC/MS/MS
LTB4
*
0.03*
(parts/million of PA)
70.28
50.49
49.72
32.29
HPLC/MS/MS
5 HETE
*
*
Unable
(parts/million of PA)
9.98
6.78
4.53
4.22
HPLC/MS/MS
12 HETE
*
Unable
(parts/million of PA)
12.49
6.62
7.93
5.23
HPLC/MS/MS
15 HETE
*
*
0.23
(parts/million of PA)
15.48
12.80
6.72
6.13
HPLC/MS/MS
EXC4
0.79
(parts/million of PA)
2.09
2.59
1.41
1.61
HPLC/MS/MS
EXD4
0.69
(parts/million of PA)
2.12
1.97
2.57
2.22
HPLC/MS/MS
EXE4
0.95
(parts/million of PA)
7.06
3.82
3.79
3.65
HPLC/MS/MS
8-iso-PGF2α
0.09
(parts/million of PA)
0.68
0.76
0.67
0.73
GC/MS
Median (25% and 75% percentiles). AIA: aspirin-induced asthma. ATA: aspirin-tolerant asthma. PA: palmitic acid.
*
-values < 0.05; AIA versus ATA at baseline or after the challenge. -values:
* AIA versus ATA at baseline.
*baseline versus challenge in AIA.
*baseline versus challenge in ATA.
